

**IN THE SUPREME COURT OF VICTORIA
AT MELBOURNE
COMMERCIAL COURT
GROUP PROCEEDINGS LIST**

S ECI 2020 04505

BETWEEN:

**NICHOLAS JOHN GEHRKE & ANOR (according to the
Schedule)**

Plaintiffs

- and -

**NOUMI LIMITED (FORMERLY FREEDOM FOODS GROUP
LIMITED) (ACN 002 814 235) & ANOR (according to the
Schedule)**

Defendants

ORDER

JUDGE: The Honourable Justice Delany

DATE MADE: 25 June 2025

ORIGINATING PROCESS: Writ filed on 7 December 2020

HOW OBTAINED: At hearing of plaintiffs' application dated 11 April

ATTENDANCE: N/A

OTHER MATTERS:

- A. This Order is made pursuant to Rule 59.07(1) of the *Supreme Court (General Civil Procedure) Rules 2015*.
- B. The Court notes that the Plaintiffs have provided an undertaking to the Court by themselves and as the representative party who commenced the proceedings for and on behalf of Eligible Group Members, that the Plaintiffs (when acting on their own behalf and on behalf of the Eligible Group Members) will not take any step to seek to recover any of the sum the subject of the compensation order made in paragraph 11 below other than by way of a Section 1317QF Application to seek distribution to Eligible Group Members of some or all of the pecuniary penalty amount to be paid by the First Defendant ('Noumi') pursuant to the Pecuniary Penalty Order.



- C. The Court notes that the orders sought in paragraphs 9, 10 and 11 below are sought with the consent of Noumi.
- D. Unless otherwise defined herein, the capitalised terms used in paragraphs 9 and 10 below have the meaning ascribed to them in the Amended Statement of Agreed Facts dated 15 April 2025 at Schedule A to these Orders.

THE COURT ORDERS THAT:

‘Eligible Group Members’ means all group members in the Proceeding who during the period between 29 August 2019 to 25 May 2020 (inclusive) acquired:

- a) an interest in fully paid ordinary shares in Noumi (‘Noumi Shares’);
- b) an interest in American Depositary Receipts that represent Noumi Shares; and/or
- c) long exposure to Noumi Shares by entering into equity swap confirmations in respect of ordinary shares in Noumi,

and who have not validly opted out of the proceeding.

Pecuniary Penalty Order means the Order made by the Federal Court of Australia in proceeding No. NSD 163 of 2023 on 5 August 2024 that Noumi pay a pecuniary penalty of \$5 million in the following instalments:

- a) \$2,000,000 within 28 days of 5 August 2024;
- b) \$1,500,000 within 12 months of 5 August 2024; and
- c) \$1,500,000 within 24 months of 5 August 2024.

Section 1317QF Application means any application made by the Plaintiffs (on behalf of Eligible Group Members) in the Federal Court of Australia proceeding number NSD 163 of 2023 that some or all of the pecuniary penalty to be paid pursuant to the Pecuniary Penalty Order be distributed to Eligible Group Members to compensate Eligible Group Members in a manner on terms to be fixed by the Federal Court.

Approval order

1. Pursuant to section 33ZF of the *Supreme Court of Victoria Act 1986* (Vic) (‘the Supreme Court Act’) that the Plaintiffs be authorised nunc pro tunc to enter into the Deed of Settlement dated 16 October 2024 (‘Deed of Settlement’) on behalf of each group member.
2. Pursuant to section 33V(1) of the Supreme Court Act that the settlement in the terms contained in the Deed of Settlement dated 16 October 2024 be approved.
3. Pursuant to section 33ZB of the Supreme Court Act that the settlement be binding on the parties to the Deed of Settlement dated 16 October 2024 and the Group Members.



4. Pursuant to section 33V and 33ZF of the Supreme Court Act that the draft Settlement Distribution Scheme ('SDS') and the draft distribution scheme regarding the Penalty Sum ordered in Federal Court Proceeding No. NSD 163 of 2023 ('ASIC Penalty SDS'), sent to the Chambers of the Honourable Justice Delany on 16 April 2025 be approved.
5. Pursuant to s 33ZF of the Act, Mr Jeremy Alexander Zimet of Phi Finney McDonald be appointed Administrator (as defined in the Deed of Settlement) ('Administrator') of the SDS and the ASIC Penalty SDS.
6. The legal costs payable to the solicitors for the Plaintiffs and Group Members, Slater and Gordon Limited and Phi Finney McDonald Pty Limited, be calculated as a percentage of the amount of the Settlement Sum (as defined by the SDS), that payment being the amount of 22% inclusive of GST made subject to any further order by the Order of the Honourable Justice Nichols on 8 November 2022, with such payment to be shared equally between the two firms of solicitors.
7. Liability for payment of the legal costs pursuant to paragraph 11 be shared among the Plaintiffs and all Registered Group Members.
8. Pursuant to section 33V(2) and/or section 33ZF of the Supreme Court Act that the following distributions from the Settlement Fund (as defined in the SDS) be approved:
 - (a) The Plaintiffs' Reimbursement Payment, as defined in the SDS, of an amount of \$35,000.00 to be shared equally by the Plaintiffs;
 - (b) The Plaintiffs' Costs, as defined in the SDS, in an amount of \$9.46 million;
 - (c) The Plaintiffs' Administration Costs, as defined in the SDS, in an amount up to \$399,983.61 (GST inclusive), comprising \$328,501.21 (including GST) to be expended on administering the SDS and \$71,482.40 (including GST) to be administering the ASIC Penalty SDS, to be paid in accordance with the SDS and ASIC Penalty SDS; and
 - (d) Distributions to Group Members, as provided for in the SDS.

Declarations and Compensation Order

9. A declaration pursuant to s 1317E(1) of the *Corporations Act 2001* (Cth) ('Corporations Act') that, in the period on and from 29 August 2019 until 25 May 2020, Noumi contravened s 674(2) of the Corporations Act by failing to notify the ASX of the FY19 Information, namely that:
 - (a) the FY19 Disclosed Inventories (being the inventories disclosed as current assets in the FY19 Financial Report) were \$120.2 million which included Not Saleable Inventory of approximately \$31.77 million;
 - (b) Noumi had not made sufficient or adequate provisions and had failed to write down the value of the FY19 Disclosed Inventories to account for the Not Saleable Inventory;
 - (c) the FY19 Disclosed Inventories were overstated by approximately \$31.77 million as a result of the inclusion of the Not Saleable Inventory;



- (d) by reason of one or more of the matters referred to in subparagraphs (a)-(c) above, the FY19 Disclosed Inventories were not recorded in the FY19 Financial Report in accordance with Noumi's Inventory Accounting Policy; and
 - (e) by reason of one or more of the matters referred to in subparagraphs (a)-(d) above, the financial statements and notes in the FY19 Financial Report did not give a true or fair view of the financial position and performance of Noumi.
10. A declaration pursuant to s 1317E(1) of the Act that, in the period on and from 27 February 2020 until 25 May 2020, the First Defendant contravened s 674(2) of the Act by failing to notify the ASX of the HY20 Inventory Information and the HY20 Revenue Information (together, the HY20 Combined Information), namely that:
- (a) the HY20 Disclosed Inventories (being the inventories disclosed as current assets in the HY20 Financial Report) were \$122.3 million which included Not Saleable Inventory of approximately \$36.6 million;
 - (b) Noumi had not made sufficient or adequate provisions and/or had failed to write- down the value of the HY20 Disclosed Inventories, to account for the Not Saleable Inventory;
 - (c) the HY20 Disclosed Inventories were overstated by approximately \$36.6 million as a result of the inclusion of the Not Saleable Inventory;
 - (d) by reason of one or more of the matters referred to in subparagraphs (a)-(c) above, the HY20 Disclosed Inventories were not recorded in the HY20 Financial Report in accordance with Noumi's Inventory Accounting Policy;
 - (e) the HY20 Disclosed Revenue (being the revenue from sale of goods disclosed in the HY20 Financial Report) included the Lactoferrin Invoice Amounts despite the existence of the Non-Revenue Information (being that in the period from 1 July 2019 until 31 December 2019, no lactoferrin the subject of the Lactoferrin Invoices was delivered to Interfood, Interfood had the right to cancel the order because CNCA and sample approval had not been obtained by June 2019 and no payment was made by Interfood to Noumi in respect of the Lactoferrin Invoices);
 - (f) Noumi failed to reduce the value of the HY20 Disclosed Revenue to account for the Non-Revenue Information;
 - (g) the HY20 Disclosed Revenue was overstated by at least \$9.8 million as a result of the Non-Revenue Information;
 - (h) the HY20 Disclosed Profit included the Lactoferrin Invoice Amounts despite the existence of the Non-Revenue Information and the Lactoferrin Profit Information (being that the Lactoferrin Invoice Amounts contributed at least \$8.5 million towards Noumi's gross profit recorded in the HY20 Financial Report);
 - (i) the HY20 Disclosed Profit was overstated by at least \$8.5 million as a result of the Non-Revenue Information and the Lactoferrin Profit Information;
 - (j) by reason of one or more of the matters referred to in subparagraphs (e) to (i) above, the HY20 Disclosed Revenue and the HY20 Disclosed Profit were not



recorded in the HY20 Financial Report in accordance with the Revenue Accounting Policy; and

- (k) by reason of one or more of the matters referred to in subparagraphs (a)-(j) above, the financial statements and notes in the HY20 Financial Report did not give a true or fair view of the financial position and performance of Noumi.
11. An order pursuant to s 1317HA of the Corporations Act that Noumi compensate Eligible Group Members in respect of damage suffered by them as a result of the contraventions of s 674(2) of the Corporations Act referred to in paragraph 9 and 10 above, in the amount of \$5 million (in total for all Eligible Group Members), but with payment of such compensation by Noumi to Eligible Group Members to be limited to the amount which Eligible Group Members may receive (if any) by way of distribution of some or all of the pecuniary penalty amount of \$5 million to be paid by Noumi in instalments pursuant to the Pecuniary Penalty Orders, pursuant to any Section 1317QF Application which has or may be made by or on behalf of Eligible Group Members.

Confidentiality

12. The Plaintiffs have leave to file in redacted form as identified in paragraph 13 below the following documents:
- (a) Eleventh Affidavit of Emma Olivia Pelka-Caven affirmed on 25 March 2025;
 - (b) Twelfth Affidavit of Emma Olivia Pelka-Caven affirmed on 25 March 2025;
 - (c) Sixth Affidavit of Jeremy Alexander Zimet affirmed on 25 March 2025; and
 - (d) Seventh Affidavit of Jeremy Alexander Zimet affirmed on 25 March 2025.
 - (e) First Affidavit of Victoria Louise Sparks affirmed on 16 April 2025; and
 - (f) Eighth Affidavit of Jeremy Alexander Zimet affirmed on 16 April 2025.
13. Each item of redaction listed in the table of redactions annexed as Schedule B to this Order to be made confidential and not be published or made available to any person without the leave of the Court, subject to:
- (a) the parties' right to provide the confidential materials to the Federal Court of Australia on a confidential basis, and solely for the purpose of the Section 1317QF Application; and
 - (b) the plaintiffs' right to provide the materials confidential only to the plaintiffs (but not to Noumi) to the Australian Securities Investment Commission on a confidential basis and solely for the purpose of the Section 1317QF Application.

Unregistered group members

14. Pursuant to sections 33V and 33ZF of the Supreme Court Act, the following Group Members, being Group Members who did not register in or opt out of the proceeding in accordance with the Order made by the Honourable Justice Nichols on 28 September 2023 ('September Order'), are deemed to be registered Group Members and are entitled to receive any distribution from the Settlement Sum in accordance with the SDS:



- (a) the Group Members listed in Schedule C as First Cohort Registered Group Members, being:
 - (i) the 36 Group Members identified in paragraph 159 of the Honourable Justice Delany's reasons dated 25 June 2025 and any revisions to those reasons ('Ruling'), being Group Members who sought to register their claims to participate in the proceeding within two days of the registration deadline of 15 November 2023 (Registration Deadline));
 - (ii) the 8 Group Members who sought to register their claims to participate in the proceeding more than two days after the Registration Deadline but within November 2023 and are identified in paragraph 162 of the Ruling as being Group Members who are allowed to participate in the settlement;
 - (iii) the 2 Group Members who sought to register their claims after November 2023 and are identified in paragraph 163(a) of the Ruling as being Group Members who are allowed to participate in the settlement;
 - (b) the 27 Group Members listed in Schedule D as Second Cohort Registered Group Members, being the persons who:
 - (i) did not register in or opt out of the proceeding in accordance with the September Order and sought to register their claims pursuant to the Order made by the Honourable Justice Nichols on 23 January 2025; and
 - (ii) are identified in paragraphs 169, 171, 175, 178, 180, 181, 182 and 183 of the Ruling as being Group Members who are allowed to participate in the settlement.
15. Pursuant to section 33ZB and 33ZF of the Supreme Court Act, any Group Member who:
- (a) has not registered by 31 October 2024 in accordance with the Order made by Justice Nichols on 28 September 2023 (as varied by Orders of Associate Justice Gobbo on 7 May 2024, 31 May 2024, 18 June 2024, 1 July 2024, 16 August 2024, 19 August 2024, 18 September 2024 and 23 September 2024); and
 - (b) has not been deemed a registered Group Member in accordance with order 14,
- will remain a Group Member for all purposes of this proceeding but shall not be permitted to share in the Settlement Sum in accordance with the settlement approved by the Court.

Other orders

- 16. All previous costs orders, save for the Order of the Honourable Justice Nichols made 8 November 2022, as between the Plaintiffs, the First Defendant and the Second Defendant be vacated.
- 17. Subject to paragraph 18, the proceeding as between the Plaintiffs, the Group Members, the First Defendant and the Second Defendant be dismissed with effect from the date of the completion of the administration of the SDS, being the date on which the final distribution from the Settlement Fund (as defined by the SDS) is confirmed by the Administrator.



18. The parties have leave to apply in respect of any matters in connection with the administration of the SDS and the Penalty Sum SDS.
19. There be no further order as to costs in the proceeding as between the Plaintiffs, the Group Members, the First Defendant and the Second Defendant.

DATE AUTHENTICATED: 27 June 2025



The Hon. Justice Delany

SCHEDULE OF PARTIES

NICHOLAS JOHN GEHRKE

First Plaintiff

LESTER BUCH

Second Plaintiff

- and -

NOUMI LIMITED (FORMERLY FREEDOM
FOODS GROUP LIMITED) (ACN 002 814 235)

First Defendant

DELOITTE TOUCHE TOHMATSU (A FIRM)
(ABN 74 490 121 060)

Second Defendant

SCHEDULE A – AMENDED STATEMENT OF AGREED FACTS DATED 15 APRIL 2025

**IN THE SUPREME COURT OF VICTORIA AT MELBOURNE
COMMERCIAL COURT
GROUP PROCEEDINGS LIST**

S ECI 2020 04505

BETWEEN

NICHOLAS JOHN GEHRKE AND LESTER BUCH

Joint Plaintiffs

and

NOUMI LIMITED (ACN 002 814 235)

First Defendant

and

DELOITTE TOUCHE TOHMATSU (A FIRM) (ABN 74 490 121 060)

Second Defendant

AMENDED STATEMENT OF AGREED FACTS

Date of Document: 15 April 2025 Solicitors Code: 339

Filed on behalf of: The Plaintiffs DX: N/A

Prepared by: Slater and Gordon Lawyers Telephone: +61 3 9190 0595
Level 35, 530 Collins Street
Melbourne, VIC, 3000

Ref: M630474
Email: Emma.PC@slatergordon.com.au

1. This Statement of Agreed Facts is filed jointly by the **Plaintiffs**, Nicholas John Gehrke and Lester Buch, and the first defendant, Noumi Limited (formerly named Freedom Foods Group Limited) (**FFG**).
2. It sets out the facts agreed between the Plaintiffs and FFG for the purpose of this proceeding between the Plaintiffs and FFG which are ‘agreed facts’ in the proceeding within the meaning of s 191(1) of the Evidence Act 2008 (Vic).
3. In this Statement of Agreed Facts, the following terms have the following meaning:
 - (a) the **Act** means the *Corporations Act 2001* (Cth).
 - (b) **ASX** means the Australian Securities Exchange.

- (c) **FFG** means Noumi Limited (formerly named Freedom Foods Group Limited) (ACN 002 814 235).
- (d) **FFG Shares** means an interest in fully paid ordinary shares of FFG.
- (e) **FY19 Disclosed Inventories** means the current assets consisting of inventories valued at \$120.2 million held by FFG as at 30 June 2019.
- (f) **FY19 Financial Report** means FFG's financial report for the financial year ending 30 June 2019 provided to the ASX on 29 August 2019.
- (g) **FY19 Information** means:
 - i. On and from 29 August 2019 until 25 May 2020:
 - a. the FY19 Disclosed Inventories were \$120.2 million which included Not Saleable Inventory of approximately \$31.77 million;
 - b. FFG had not made sufficient or adequate provisions and had failed to write down the value of the FY19 Disclosed Inventories to account for the Not Saleable Inventory;
 - c. the FY19 Disclosed Inventories were overstated by approximately \$31.77 million as a result of the inclusion of the Not Saleable Inventory;
 - d. by reason of one or more of the matters referred to in subparagraphs (a)-(c) above, the FY19 Disclosed Inventories were not recorded in the FY19 Financial Report in accordance with FFG's Inventory Accounting Policy; and
 - e. by reason of one or more of the matters referred to in subparagraphs (a)-(d) above, the financial statements and notes in the FY19 Financial Report did not give a true or fair view of the financial position and performance of FFG.
- (h) **HY20 Combined Information** means the HY20 Inventory Information and the HY20 Revenue Information.

- (i) **HY20 Disclosed Inventories** means the current assets which included inventories valued at \$122.3 million held by FFG as at 31 December 2019.
- (j) **HY20 Disclosed Profit** means the disclosure in the HY20 Financial Report that for the half year ending 31 December 2019, FFG achieved gross profit of \$81.2 million and profit before tax of \$6.9 million.
- (k) **HY20 Disclosed Revenue** means the disclosure in the HY20 Financial Report that for the half year ending 31 December 2019, FFG received revenue from sale of goods of \$299.7 million.
- (l) **HY20 Financial Report** means FFG's financial report for the half year ending 31 December 2019 provided to the ASX on 27 February 2020.
- (m) **HY20 Inventory Information** means:
 - i. On and from 27 February 2020 until 25 May 2020:
 - a. the HY20 Disclosed Inventories were \$122.3 million which included Not Saleable Inventory of approximately \$36.6 million;
 - b. FFG had not made sufficient or adequate provisions and/or had failed to write down the value of the HY20 Disclosed Inventories, to account for the Not Saleable Inventory;
 - c. the HY20 Disclosed Inventories were overstated by approximately \$36.6 million (made up as identified in (a) above) as a result of the inclusion of the Not Saleable Inventory;
 - d. by reason of one or more of the matters referred to in subparagraphs (a)-(c) above, the HY20 Disclosed Inventories were not recorded in the HY20 Financial Report in accordance with the Inventory Accounting Policy; and
 - e. by reason of one or more of the matters referred to in subparagraphs (a)-(d) above, the financial statements and notes in the HY20 Financial Report did not give a true or fair view of the financial position and performance of FFG.

(n) **HY20 Revenue Information** means:

- i. From 27 February 2020 until 25 May 2020:
 - a. the HY20 Disclosed Revenue included the Lactoferrin Invoice Amounts despite the existence of the Non-Revenue Information;
 - b. FFG had failed to reduce the value of the HY20 Disclosed Revenue to account for the Non-Revenue Information;
 - c. the HY20 Disclosed Revenue was overstated by at least \$9.8 million as a result of the Non-Revenue Information;
 - d. the HY20 Disclosed Profit included the Lactoferrin Invoice Amounts despite the existence of the Non-Revenue Information and the Lactoferrin Profit Information;
 - e. the HY20 Disclosed Profit was overstated by at least \$8.5 million as a result of the Non-Revenue Information and the Lactoferrin Profit Information;
 - f. by reason of one or more of the matters referred to in subparagraphs (a)-(e) above, the HY20 Disclosed Revenue and the HY20 Disclosed Profit were not recorded in the HY20 Financial Report in accordance with the Revenue Accounting Policy; and
 - g. by reason of one or more of the matters referred to in subparagraphs (a)-(f) above, the financial statements and notes in the HY20 Financial Report did not give a true or fair view of the financial position and performance of FFG.

(o) **Inventory Accounting Policy** means the accounting policy that FFG had in place at all material times, which was consistent with Australian accounting standards and required that its inventory be valued at the lower of cost and net realisable value, being the estimated selling price in the ordinary course of business, less estimated costs of completion and the estimated costs necessary to make the sale.

(p) **Interfood** means Interfood Singapore Pte Ltd.

(q) **Lactoferrin Invoice Amounts** means the value of the Lactoferrin Invoices, which amounted to a total sale price of USD\$6.8 million, being at least AUD\$9.8 million.

- (r) **Lactoferrin Invoices** means the 16 invoices in respect of the sale of lactoferrin to Interfood raised by FFG between 1 July 2019 and 31 December 2019.
- (s) **Lactoferrin Profit Information** means the fact that the Lactoferrin Invoice Amounts contributed at least \$8.5 million towards FFG's gross profit recorded in the HY20 Financial Report.
- (t) **Non-Revenue Information** means the fact that in the period from 1 July 2019 until 31 December 2019, no lactoferrin the subject of the Lactoferrin Invoices was delivered to Interfood, and Interfood had the right to cancel the order because Certification and Accreditation Administration of China (CNCA) and sample approval had not been obtained by June 2019 and no payment was made by Interfood to FFG in respect of the Lactoferrin Invoices.
- (u) **Not Saleable Inventory** means the inventory recorded in QAD that was assigned a non-nettable status code included some stock that never existed (the "virtual stock"), which had been rejected for quality reasons, had expired or was subject to MLOR requirements, or was otherwise stock for which no sale price or other monetary benefit was likely to be received.
- (v) **QAD** means the enterprise resource planning software FFG used to manage and monitor its procurement, customer orders, order management, inventory, invoicing, and financials. QAD was the application through which FFG carried (by number of items) and inventory values (in dollars).
- (w) **Plaintiffs** means Nicholas John Gehrke and Lester Buch, being the plaintiffs in this proceeding.

Contraventions

- 4. At all material times on and from about 1 May 2019 until 25 May 2020:
 - (a) the ASX was a "listing market" within the meaning of s 111AE(1) of the Act;
 - (b) FFG's shares were:
 - i. "ED Securities" within the meaning of s 111AE(1) of the Act;
 - ii. "quoted ED securities" within the meaning of s 111AM of the Act.

- (c) FFG was:
 - i. a “disclosing entity” within the meaning of s 111AC(1) of the Act;
 - ii. a “listed disclosing entity” within the meaning of s 111AL(1) of the Act;
 - iii. subject to the continuous disclosure requirements of s 674 of the Act pursuant to s 111AP(1) of the Act; and
 - iv. subject to, and bound, by the ASX Listing Rules.
- 5. On and from about 29 August 2019 until 25 May 2020:
 - (a) FFG was aware of the FY19 Information because Mr Rory Macleod and Mr Campbell Nicholas were officers of FFG and they knew or ought reasonably to have come into possession of the FY19 Information;
 - (b) the FY19 Information was not generally available;
 - (c) the FY19 Information was information that a reasonable person would expect, if it were generally available, to have a material effect on the price or value of FFG’s shares;
 - (d) Listing Rule 3.1 required immediate disclosure to ASX of the FY19 Information; and
 - (e) FFG did not notify or disclose to ASX the FY19 Information.
- 6. On and from about 27 February 2020 until 25 May 2020:
 - (a) FFG was aware of the HY20 Inventory Information and the HY20 Revenue Information because Mr Rory Macleod and Mr Campbell Nicholas were officers of FFG and they ought reasonably to have come into possession of the HY20 Inventory Information and the HY20 Revenue Information;
 - (b) the HY20 Inventory Information and the HY20 Revenue Information was not generally available;

- (c) the HY20 Combined Information was information that a reasonable person would expect, if it were generally available, to have a material effect on the price or value of FFG's shares;
 - (d) Listing Rule 3.1 required immediate disclosure to ASX of the HY20 Combined Information; and
 - (e) FFG did not notify or disclose to the ASX the HY20 Combined Information.
7. FFG engaged in two contraventions of s 674(2) of the Act:
- (a) by reason of the matters referred to in paragraph 5 above, by failing to notify the ASX of the FY19 Information on and from about 29 August 2019 until at least 25 May 2020;
 - (b) by reason of the matters referred to in paragraph 6 above, by failing to notify the ASX of the HY20 Combined Information on and from about 27 February 2020 until at least 25 May 2020.
8. Each of the contraventions referred to in paragraph 7 above materially prejudiced the interests of shareholders (because it meant that FFG shares were traded, and shareholders bought and sold their shares, in an uninformed market from 29 August 2019 until 25 May 2020 and because non-disclosure of the information harmed FFG and caused its share price to collapse after the information was belatedly revealed).
9. Group members in this proceeding who during the period between 29 August 2019 to 25 May 2020 (inclusive) acquired:
- (a) FFG Shares;
 - (b) an interest in American Depositary Receipts that represent FFG Shares; and/or
 - (c) long exposure to FFG Shares by entering into equity swap confirmations in respect of ordinary shares in FFG,

suffered damage within the meaning of s 1317HA(1) of the Act which resulted from the contraventions of s 674(2) of the Act referred to in paragraph 7 above, in the sum of at least \$5 million.

SCHEDULE B: CONFIDENTIAL MATERIALS

Eleventh Affidavit of Emma Pelka-Caven affirmed on 25 March 2025

Item	Page	Affidavit paragraph / exhibit reference	Basis for assertion
1.	27	108	Confidential – reference to negotiations with defendant subject to confidentiality.
2.	27	111	Confidential – reference to Conditions Precedent material subject to confidentiality, per cl 4(c)(i) of the Deed of Settlement.
3.	28	117	Confidential – reference to Conditions Precedent material subject to confidentiality, per cl 4(c) of the Deed of Settlement.
4.	28	119	Confidential – reference to Conditions Precedent material subject to confidentiality, per cl 4(c) of the Deed of Settlement.
5.	29	122	Confidential – reference to Conditions Precedent material subject to confidentiality, per cl 4(c) of the Deed of Settlement.
6.	29	123	Legal professional privilege – litigation privilege; assessment of claim.
7.	38	176	Legal professional privilege – litigation privilege; assessment of claim; calculating loss estimates.
8.	39 – 40	181	Confidential – reference to Conditions Precedent material subject to confidentiality, per cl 4(c) of the Deed of Settlement.
9.	40	181(d)-(f)	Legal professional privilege – litigation privilege; assessment of claim.
10.	40 – 41	182	Confidential – reference to Conditions Precedent material subject to confidentiality, per cl 4(c) of the Deed of Settlement.
11.	41	184	Confidential – reference to Conditions Precedent material subject to confidentiality, per cl 4(c) of the Deed of Settlement.
12.	42	185	Legal professional privilege – legal advice privilege; assessment of claim.
13.	42	186	Confidential – reference to Conditions Precedent material subject to confidentiality, per cl 4(c) of the Deed of Settlement.
14.	42	187	Legal professional privilege – litigation privilege; assessment of claim.
15.	42 – 43	188	Confidential – reference to material subject to confidentiality, per cl 4(c) of the Deed of Settlement. Legal professional privilege – litigation privilege; assessment of claim.

16.	43	192	Legal professional privilege – litigation privilege; assessment of claim.
17.	43	193	Legal professional privilege – legal advice privilege; assessment of claim.
18.	44	194	Legal professional privilege – litigation privilege; assessment of claim.
19.	44 – 45	195 – 200	Legal professional privilege – litigation privilege; calculating loss estimates.
20.	48	217	Legal professional privilege – litigation privilege; calculating loss estimates.
21.	48 – 49	218	Legal professional privilege – litigation privilege; calculating loss estimates.
22.	49	219	Legal professional privilege – litigation privilege; calculating loss estimates.
23.	49	220	Legal professional privilege – litigation privilege; assessment of claim; calculating loss estimates.
24.	49	221	Legal professional privilege – litigation privilege; assessment of claim; calculating loss estimates.
25.	54	238	Legal professional privilege – litigation privilege; assessment of claim; calculating loss estimates.
26.	54 – 55	239	Legal professional privilege – litigation privilege; assessment of claim; calculating loss estimates.
27.	309 – 370	Entirety of exhibited Deed of Settlement	Confidential – Deed of Settlement subject to confidentiality per cl 14 of the Deed of Settlement.
28.	371 – 2381	Entirety of exhibited Affidavit of Justin Coss	Confidential – Conditions Precedent material subject to confidentiality, per cl 4(c) of the Deed of Settlement.
29.	2382 – 2441	Entirety of exhibited Independent Expert Report of Marcus Ayres	Confidential – Conditions Precedent material subject to confidentiality, per cl 4(c) of the Deed of Settlement.
30.	2442 – 2543	Entirety of exhibited Independent Valuation Report of Grant Thornton	Confidential – Conditions Precedent material subject to confidentiality, per cl 4(c) of the Deed of Settlement.
31.	2544 – 2548	Entirety of exhibited Side Deed of Settlement	Confidential – Side Deed of Settlement subject to confidentiality per cl 14 of the Deed of Settlement.
32.	2549 – 2639	Entirety of exhibited Counsel Opinion	Legal professional privilege – litigation privilege, assessment of claim, calculating loss estimates. See also: <i>Burke v Ash Sounds Pty Ltd (No 4)</i> [2020] VSC 581 at [22] (Incerti J); <i>Cantor v Audi Australia Pty Limited (No 5)</i> [2020] FCA 637 at [275]-[278] (Foster J).
33.	2630 – 2632	Entirety of Letter	Confidential – Conditions Precedent material subject to confidentiality, per cl 4(c) of the Deed of Settlement.

Twelfth Affidavit of Emma Pelka-Caven affirmed on 25 March 2025

Item	Page	Affidavit paragraph / exhibit reference	Basis for assertion
1.	8	30	Confidential – information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
2.	9	31	Confidential – information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
3.	12	41(c)	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
4.	13	47(c)	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
5.	14	51	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
6.	15	52	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
7.	15	54	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
8.	16	56	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
9.	17	60	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
10.	17 – 18	63	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
11.	18	67	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be

			expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
12.	19	69	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
13.	19	71	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
14.	21	79	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
15.	23	82(c)	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
16.	24	84(b)	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
17.	25	86	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
18.	27	94	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
19.	27	96	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
20.	31	105(b)	Confidential – conduct of Slater and Gordon’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7])
21.	31 – 32	107	Legal professional privilege – litigation privilege; assessment of claim.
22.	32	108	Legal professional privilege – litigation privilege; assessment of claim.

Sixth Affidavit of Jeremy Zimet affirmed on 25 March 2025

Item	Page	Affidavit paragraph / exhibit reference	Basis for assertion
1.	14	40	Legal professional privilege – litigation privilege; assessment of claim; calculating loss estimates.
2.	14-15	42	Legal professional privilege – litigation privilege; assessment of claim; calculating loss estimates.
3.	15	43	Legal professional privilege – litigation privilege; assessment of claim; calculating loss estimates.
4.	15	44	Legal professional privilege – litigation privilege; assessment of claim; calculating loss estimates.
5.	15	45	Legal professional privilege – litigation privilege; assessment of claim; calculating loss estimates.
6.	16	46	Legal professional privilege – litigation privilege; assessment of claim; calculating loss estimates.
7.	16	47	Legal professional privilege – litigation privilege; assessment of claim; calculating loss estimates.
8.	16	48	Legal professional privilege – litigation privilege; assessment of claim; calculating loss estimates.
9.	20	64	Legal professional privilege – legal advice privilege; assessment of claim.
10.	109	Partly of JAZ-7 exhibited Omni Bridgeway Client Services Costs Proposal	Confidential – Omni Bridgeway’s conduct of business
11.		Entirety of Confidential Exhibit JAZ-8 Plaintiffs Reimbursement Schedule	Legal professional privilege – legal advice privilege; assessment of claim.

Seventh Affidavit of Jeremy Zimet affirmed on 25 March 2025

Item	Page	Affidavit paragraph / exhibit reference	Basis for assertion
1.	19	77	Confidential – conduct of PFM’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7]).
2.	19	78	Confidential – conduct of PFM’s business; information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7]).

3.	20	79	Legal professional privilege – litigation privilege; assessment of claim.
4.	2-3	Part of Exhibit JAZ-11 Paginated Bundle of Exhibits	Confidential – information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7]).
5.	11-13	Part of Exhibit JAZ-11 Paginated Bundle of Exhibits	Confidential – information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7]).
6.	27	Part of exhibit JAZ-11 Paginated Bundle of Exhibits	Confidential – information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7]).
7.	30-31	Part of exhibit JAZ-11 Paginated Bundle of Exhibits	Confidential – information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7]).
8.	38-39	Part of exhibit JAZ-11 Paginated Bundle of Exhibits	Confidential – information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7]).
9.	49	Part of exhibit JAZ-11 Paginated Bundle of Exhibits	Confidential – information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7]).
10.	57	Part of exhibit JAZ-11 Paginated Bundle of Exhibits	Confidential – information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7]).
11.	60-63	Part of exhibit JAZ-11 Paginated Bundle of Exhibits	Confidential – information that might reasonably be expected to confer a tactical advantage on another party to the proceeding (Practice Note Gen 10 Group Proceedings, [13.7]).

First Affidavit of Victoria Louise Sparks affirmed on 16 April 2025

Item	Page	Affidavit paragraph / exhibit reference	Basis for assertion
1.	4-2329	Entirety of VLS-1	Confidential – reference to Conditions Precedent material subject to confidentiality, per cl 4(c) of the Deed of Settlement.

Eighth Affidavit of Jeremy Alexander Zimet affirmed on 16 April 2025

Item	Page	Affidavit paragraph / exhibit reference	Basis for assertion
1.	20	Part of Exhibit JAZ-13	Confidential – reference to identifying Group member information.
2.	31	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information.
3.	32	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information.
4.	33	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
5.	34	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information.
6.	29	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
7.	38	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information.
8.	39	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
9.	41-42	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.

10.	43	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
11.	45	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
12.	46-47	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
13.	48	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
14.	49	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
15.	51	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member

			name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
16.	52-53	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
17.	54	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
18.	55-56	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
19.	56-57	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
20.	58	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in

			their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
21.	60	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
22.	61-62	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
23.	63	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
24.	65	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) in this item are unredacted because confidentiality is not claimed in respect of any Group member names (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
25.	66	Part of Exhibit JAZ-13	Confidential – reference to Group member contact information. For completeness, group member name(s) and addresses in this item are unredacted because confidentiality is not claimed in respect of any Group member names or addresses (a) which have been disclosed in their affidavit evidence; and/or (b) where the Group member was given prior notice that their name and information or

			documentation relevant to their registration will be disclosed to the Court and defendants, and may be disclosed publicly.
26.	N/A	Part of Exhibit JAZ-15	Confidential – reference to identifying Group member information.
27.	7-9	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
28.	10-13	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
29.	14-17	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
30.	18-19	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
31.	20-24	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
32.	25-29	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
33.	30-33	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
34.	34-37	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
35.	38-39	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
36.	39	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
37.	40-43	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
38.	44-47	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
39.	48	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
40.	49-50	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
41.	51-52	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
42.	53-54	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.

43.	55	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
44.	56	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
45.	57-60	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
46.	61-64	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
47.	65-68	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
48.	69	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
49.	70	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
50.	71	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
51.	72	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
52.	73-77	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
53.	78-79	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
54.	80-81	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
55.	82-85	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
56.	86-132	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
57.	133	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
58.	134-137	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
59.	138-141	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
60.	142-145	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.

61.	146-147	Part of Exhibit JAZ-16	Confidential – reference to identifying Group member information.
-----	---------	---------------------------	--

SCHEDULE C: FIRST COHORT REGISTERED GROUP MEMBERS

Item	Plaintiff ID	Name	Ruling Paragraph reference
1.	550023	Samantha Taranto	159
2.	550128	Aust Shares Small Industrials - Discovery - USELNX	159
3.	550036	Aust Shares Small Industrials - Discovery - USQIAE	159
4.	550127	Aust Shares Small Industrials - Discovery - USTRN2	159
5.	550115	John Roberts	159
6.	550018	UTM Engineering PTY LTD	159
7.	550120	Matthew Hughes	159
8.	550121	Miska John Curtis	159
9.	550124	Maya Anne Curtis	159
10.	550125	Xiao Dan Fu	159
11.	552464	Shruti Mathur	159
12.	553160	Huiru Shirley Liao & Yun Yang	159
13.	553184	Sarem Investments Pty Ltd	159
14.	553186	Tarun Raina	159
15.	554314	Dale Anne-Maree Spon-Smith	159
16.	554312	Jackwin Pty Ltd as trustee for Winjack Retirement Fund	159
17.	554315	Karalee 01 Pty Ltd as trustee for Karalee Super Fund	159
18.	550076	Harrisson Pty Ltd as trustee for Harrisson Super Fund	159
19.	554311	Seidler Superannuation Pty Ltd	159
20.	383636	Dimension Fund Advisors as investment manager for Australian Core Equity Trust	159
21.	383640	Dimension Fund Advisors as investment manager for Asia Pacific Small Company Series	159

22.	383643	Dimension Fund Advisors as investment manager for International Vector Equity Portfolio	159
23.	383632	Dimension Fund Advisors as investment manager for Global Targeted Value Fund of Dimensional Funds plc	159
24.	383646	Dimension Fund Advisors as investment manager for Australian Sustainability Trust	159
25.	383641	Dimension Fund Advisors as investment manager for International Sustainability Core 1 Portfolio	159
26.	383642	Dimension Fund Advisors as investment manager for T.A. World ex U.S. Core Equity Portfolio	159
27.	383631	Dimension Fund Advisors as investment manager for Global Small Companies Fund of Dimensional Funds plc	159
28.	383633	Dimension Fund Advisors as investment manager for Pacific Basin Small Companies Fund	159
29.	383637	Dimension Fund Advisors as investment manager for DFA International Social Core Equity	159
30.	383634	Dimension Fund Advisors as investment manager for Multi-Factor Equity Fund	159
31.	383590	Dimension Fund Advisors as investment manager for Global Core Equity Fund of Dimensional Funds plc	159
32.	383644	Dimension Fund Advisors as investment manager for Australian Core Imputation Trust	159
33.	383635	Dimension Fund Advisors as investment manager for World ex US Core Equity Portfolio	159
34.	383645	Dimension Fund Advisors as investment manager for World ex US Core Equity Portfolio	159
35.	383639	Dimension Fund Advisors as investment manager for VA International Small Portfolio	159
36.	383638	Dimension Fund Advisors as investment manager for International Core Equity Fund of Dimensional Funds ICVC	159
37.	554416	Raymond Levis as trustee for Sammi-I Pty Ltd	162
38.	550032	Jaswinder Singh	162
39.	546988	Alan David Thompson and Judith Ann Thompson	162
40.	554558	Lake Cooper Holdings Pty Ltd	162
41.	554626	Care Superannuation Pty Ltd as trustee for Care Superannuation Fund - CRLXAE	162

42.	554633	Care Superannuation Pty Ltd as trustee for Care Superannuation Fund - CROHCE	162
43.	554634	Care Superannuation Pty Ltd as trustee for Care Superannuation Fund - CROOAE	162
44.	554635	Care Superannuation Pty Ltd as trustee for Care Superannuation Fund - CRTRAN	162
45.	554742	Nucoy Nominees Pty Ltd as trustee for D & K McAndrew S/F A/C	163(a)
46.	554783	Judy Denise Strachan as trustee for Strachan Investments Trust	163(a)

SCHEDULE D: SECOND COHORT REGISTERED GROUP MEMBERS

Item	Group member number	Name	Ruling Paragraph reference
1.	33039	Edward Falkiner	169
2.	33066	Brendan Burns	169
3.	N/A	Alan Lock	169
4.	N/A	Peter Steven Cavnoudias	169
5.	33028	Jessica Price	171
6.	33158	Jiaming Liang	171
7.	33062	Liam Silk	171
8.	N/A	Johanna Dykgraaf	171
9.	33146	Mark Leitch	175
10.	33054	Steffanie Pernase	175
11.	33137	Devin Kaplan	175
12.	33046	Wendy Reynolds	175
13.	33150	Qun Mi	175
14.	33034	Christopher White	175
15.	33031	Mark Spektor	178
16.	33040	Nhi Ai Lam Vo	178

17.	33143	Geoffrey Forday	178
18.	33061	Otto du Plooy	178
19.	33931	Nathan Willis	178
20.	33157	Lorraine Hecker	180
21.	33030	Lian Ding	180
22.	33067	Rayhana Roma	180
23.	33051	Ernesto Pereira	181
24.	33063	Jacklyn Johnston	182
25.	33147	Angela Di Felice	182
26.	33071	Ashly Wason	183
27.	33072	Robert Tohver	183